Breaking News From Pharma & Bio Ingredients Subscribe via RSS Subscribe via RSS



Viral Genetics Provides Update on VGV-1


Posted on 2006-03-31 09:52:00



Viral Genetics, Inc.  previously stated its expectation that the results of the Phase III human clinical trial conducted in South Africa would be available by today. While this expectation will not be met today, Viral Genetics expects no significant delay in the release of the results of the clinical trial conducted in South Africa.

The "TNP-001 Study" was a Phase III, double-blind, placebo-controlled, randomized, multi-center study of 137 HIV positive patients treated with either VGV-1 or placebo that began enrollment in August 2004 and completed follow up in November 2005.

Viral Genetics, Inc. is a drug discovery and development company based in Azusa, CA, developing treatments for infectious disease, autoimmune disease and immunological deficiency through its patented Thymus Nuclear Protein technology.


NEWS ARCHIVES

2008

2007

2006

2005

2004

NEWSLETTER SIGNUP